Abstract
The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.
Keywords: Mycobacterium tuberculosis, Mycobacterium avium complex, tuberculosis, drug-resistance, new targets, promising drugs, anti-TB therap, drug-combinations
Infectious Disorders - Drug Targets
Title: New Trends in Development of Antimycobacterial Compounds
Volume: 6 Issue: 2
Author(s): M. Biava, G C. Porretta, D. Deidda and R. Pompei
Affiliation:
Keywords: Mycobacterium tuberculosis, Mycobacterium avium complex, tuberculosis, drug-resistance, new targets, promising drugs, anti-TB therap, drug-combinations
Abstract: The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.
Export Options
About this article
Cite this article as:
Biava M., Porretta C. G, Deidda D. and Pompei R., New Trends in Development of Antimycobacterial Compounds, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112173
DOI https://dx.doi.org/10.2174/187152606784112173 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Synergistic Interaction Between Amide Piplartine and Antimicrobial Peptide Dermaseptin Against Schistosoma mansoni Schistosomula and Adult Worms
Current Medicinal Chemistry Structure-based Discovery of Narirutin as a Shikimate kinase Inhibitor with Anti-tubercular Potency
Current Computer-Aided Drug Design Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design An Efficient and Environmentally Benign Access Towards Synthesis of Novel 1,2,3-Triazolyl-pyrazoline Hybrids
Letters in Organic Chemistry Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Structural Biology of Bacterial Iron Uptake Systems
Current Topics in Medicinal Chemistry Recent Advances in QSAR-based Identification and Design of Anti-Tubercular Agents
Current Pharmaceutical Design Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules
Current Drug Targets Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents - a Review
Current Pharmaceutical Design Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation New Targets, New Hope: Novel Drug Targets for Curbing Malaria
Mini-Reviews in Medicinal Chemistry New insights on Ethambutol Targets in Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis
Current Protein & Peptide Science Screening of Antioxidant, Antimicrobial Activities and Chemical Contents of Edible Mushrooms Wildly Grown in the Black Sea Region of Turkey
Combinatorial Chemistry & High Throughput Screening Novel Thiazole Carboxylic Acid Derivatives Possessing a “Zinc Binding Feature” as Potential Human Glyoxalase-I Inhibitors
Letters in Drug Design & Discovery Isoniazid: an Update on the Multiple Mechanisms for a Singular Action
Current Medicinal Chemistry Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery New Vaccines and Delivery Strategies for Adult Immunization
Current Immunology Reviews (Discontinued)